The Technical AnalystExchange: OTC Sector: Healthcare Industry: Biotechnology
Living Cell Technologies Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0427
America/New_York / 24 apr 2024 @ 14:28
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 12.19 mill |
| EPS: | -0.0100 |
| P/E: | -4.27 |
| Earnings Date: | Apr 29, 2024 |
| SharesOutstanding: | 285.50 mill |
| Avg Daily Volume: | 0.0027 mill |
| RATING 2024-04-24 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.27 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -4.27 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0014 (-96.77%) $-0.0413 |
| Date: 2024-04-29 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0397 - 0.0457 ( +/- 7.03%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0427 (0.00% ) |
| Volume | 0.0000 mill |
| Avg. Vol. | 0.0027 mill |
| % of Avg. Vol | 1.681 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LVCLY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LVCLY
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.